{"entity":{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial in triple-negative breast cancer, run by Iovance Biotherapeutics, Inc., not yet recruiting.","summary":"A Study of IOV-5001 in Adults With Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07743723 by Iovance Biotherapeutics, Inc., with a registry enrolment figure of 106 participants, started 2026-09 and due to reach its primary completion in 2034-03. Interventions recorded: IOV-5001. Conditions listed: Advanced Solid Tumors; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Solid Tumors; Unresectable Solid Tumor. Triple-negative eligibility wording from the registry: \"TNBC: Participant has a histologically or pathologically confirmed diagnosis of unresectable or Stage IV breast cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07743723","url":"https://clinicaltrials.gov/study/NCT07743723"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07743723","phase":"1/2","setting":"A Phase 1/2, Multicenter, Multi-cohort, Open-label Study of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen With IOV-5001 in Participants With Previously Treated Advanced Solid Tumors","sponsor":"Iovance Biotherapeutics, Inc.","participation":[{"nct":"NCT07743723","source":"https://clinicaltrials.gov/study/NCT07743723","fetchedAt":"2026-10-07T16:56:49.835Z","studySha256":"26ff7c5f2d98da623c5b78e236784c75a22c51f8210709e4e18f2d541be51dba","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-09-15","leadSponsor":"Iovance Biotherapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":106,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2026-09","startedType":"estimated","enrolled":106,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07743723/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}